Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment
China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...
Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...
Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China
China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...
WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for...
HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the...
Shanghai HSA Unveils Measures to Boost Access to Innovative Drugs and Devices
The Healthcare Security Administration (HSA) in Shanghai has recently released a set of Measures aimed...
Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results
Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...
MicroPort MedBot’s SkyWalker Orthopedic Surgery Robot Gains TGA Approval in Australia
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...
CDE Releases Draft Guidelines for Clinical Pharmacology Research of Chemical Modified Drugs
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Pharmacological Research...
Baidu Health Partners with GSK for Shingles Disease Education Programs in China
China Internet giant Baidu’s Health Internet Hospital unit has entered into a strategic partnership with...
Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...
Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it...
Mabwell Secures Licensing Deal with Morocco’s Sothema for Biosimilar Humira
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a significant licensing and commercialization...
Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China
The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...
Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA
Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...
Sanofi to Boost CHC Unit with Full Acquisition of US Health Brand Qunol
France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to...
AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer
AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...
AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales
UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the...
Sanofi Reports 3.3% YOY Sales Growth in Q2 2023, Driven by Vaccines and Dupixent
France-based Sanofi (NASDAQ: SNY) has released its financial results for the second quarter of 2023,...
Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...